tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Potential of Neurocrine’s Osavampator in Treating Major Depressive Disorder: A Buy Recommendation by Sean Laaman
PremiumRatingsPromising Potential of Neurocrine’s Osavampator in Treating Major Depressive Disorder: A Buy Recommendation by Sean Laaman
9d ago
Neurocrine price target raised to $149 from $144 at RBC Capital
Premium
The Fly
Neurocrine price target raised to $149 from $144 at RBC Capital
25d ago
Neurocrine’s Strong Market Performance and Promising Pipeline Justify Buy Rating
Premium
Ratings
Neurocrine’s Strong Market Performance and Promising Pipeline Justify Buy Rating
2M ago
Neurocrine’s Promising Financial Outlook: Strong Crenessity Performance and Strategic Ingrezza Adjustments Drive Buy Rating
PremiumRatingsNeurocrine’s Promising Financial Outlook: Strong Crenessity Performance and Strategic Ingrezza Adjustments Drive Buy Rating
2M ago
Neurocrine price target raised to $175 from $165 at Guggenheim
Premium
The Fly
Neurocrine price target raised to $175 from $165 at Guggenheim
2M ago
Neurocrine Biosciences’ Earnings Call Highlights Growth
Premium
Company Announcements
Neurocrine Biosciences’ Earnings Call Highlights Growth
2M ago
Neurocrine price target raised to $141 from $137 at Wedbush
PremiumThe FlyNeurocrine price target raised to $141 from $137 at Wedbush
2M ago
Buy Rating for Neurocrine’s Crenessity Driven by Strong Sales and Transformative Impact on CAH Treatment
Premium
Ratings
Buy Rating for Neurocrine’s Crenessity Driven by Strong Sales and Transformative Impact on CAH Treatment
2M ago
Neurocrine price target raised to $145 from $140 at JPMorgan
Premium
The Fly
Neurocrine price target raised to $145 from $140 at JPMorgan
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100